Upcoming Announcement from Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB), a pioneering live biotherapeutics company, is gearing up to share its first quarter 2025 financial results on May 7, 2025. The management team will host a conference call alongside a live audio webcast at 8:30 a.m. ET, where attendees can expect insights into the company’s recent business developments and financial performance.
How to Participate in the Conference Call
For those interested in joining the conference call, you can dial 800-715-9871 for domestic inquiries or 646-307-1963 for international participants. It is advisable to use the conference ID number 4618787 when calling in. Alternatively, to access the live webcast, visit the "Investors and News" section of the Seres Therapeutics website.
Webcast Replay and Availability
Following the conclusion of the event, a replay of the webcast will be available on the company’s website, allowing attendees to revisit the presentation approximately two hours after it concludes. The replay service will remain accessible for about 21 days, ensuring everyone has the opportunity to catch up on the critical information shared.
About Seres Therapeutics
Seres Therapeutics, Inc. is dedicated to advancing patient care through innovative microbiome therapeutic solutions. With a strong focus on vulnerable populations, the company is at the forefront of developing groundbreaking treatments. Among its most notable achievements is VOWST™, the first FDA-approved orally administered microbiome therapeutic, recently acquired by Nestlé Health Science in 2024.
Current Therapeutic Developments
At present, Seres is actively working on SER-155, a promising therapeutic that has earned both Breakthrough Therapy designation and Fast Track designation aimed at addressing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 has shown significant promise in clinical studies, notably reducing instances of bloodstream infections and complications compared to placebo treatments.
Expanding Therapeutic Reach
Beyond SER-155, Seres has developed a robust pipeline targeting a variety of disease pathways. The company envisions broadening its therapeutic applications beyond allo-HSCT to other medically vulnerable patient groups, including oncology patients undergoing treatment, individuals requiring solid organ transplants, and those in intensive care. This expansive approach highlights Seres’ commitment to alleviating health challenges across diverse populations.
Investor and Media Relations
Investors and media representatives looking for more information can reach out to the dedicated contact team through the email provided on their website. Carlo Tanzi, Ph.D. from Kendall Investor Relations is available for inquiries and can be contacted via email.
Concluding Thoughts
As Seres Therapeutics moves closer to its next significant announcement, the anticipation around their innovative treatments and promising clinical results is palpable. Stakeholders are encouraged to keep a close eye on the company’s developments during the upcoming conference call, as it will shed light on both their financial status and future initiatives in the ever-evolving biotherapeutics landscape.
Frequently Asked Questions
What are the key goals of Seres Therapeutics?
Seres Therapeutics aims to enhance patient outcomes in medically vulnerable populations using innovative live biotherapeutics.
When is the conference call for the Q1 financial results?
The conference call is scheduled for May 7, 2025, at 8:30 a.m. ET.
How can I access the conference call?
You can join by calling 800-715-9871 for domestic participants or 646-307-1963 for international calls using the conference ID 4618787.
What is SER-155?
SER-155 is a therapeutic candidate being developed by Seres for the prevention of bloodstream infections and complications in patients undergoing allo-HSCT.
Where can I find more information about Seres Therapeutics?
More details about the company and its products can be found on the official Seres Therapeutics website.
